VERA
Vera Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -28.6% ·
share flow -7.7% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 83 | -2 | 39.21M | $1.68B | +6 | −8 |
| Q1 2026 | 88 | +8 | 35.14M | $1.43B | +11 | −3 |
| Q4 2025 | 79 | +2 | 37.37M | $1.89B | +2 | n/a |
| Q3 2025 | 14 | -1 | 22.48M | $653.29M | +1 | −3 |
| Q2 2025 | 13 | 0 | 19.02M | $448.09M | +1 | −1 |
| Q1 2025 | 10 | -4 | 8.70M | $208.98M | n/a | −4 |
| Q4 2024 | 14 | +2 | 9.43M | $398.65M | +2 | n/a |
| Q3 2024 | 11 | -1 | 7.58M | $334.97M | n/a | −1 |
| Q2 2024 | 12 | n/a | 7.20M | $260.63M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 4.75M | +8.6% | $114.21M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 2 | State Street Global Advisors ✦ (passive) | 2.08M | +2.8% | $50.03M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 1.20M | +4.3% | $28.90M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 211.79K | +286.4% | $5.09M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 189.25K | -77.4% | $4.55M | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
| 6 | Millennium Management ✦ | 134.89K | +73.7% | $3.24M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 54.00K | +11.1% | $1.30M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 40.60K | +13.7% | $975,212 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Wellington Management ✦ | 19.06K | +5.8% | $457,845 | 0.0% | ▲ Add | 4 | SEC ↗ ×4 |
| 10 | Two Sigma Investments ✦ | 9.55K | -77.0% | $229,415 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Adage Capital Partners | $20.30M | was 0.0% |
| Point72 Asset Management | $8.21M | was 0.0% |
| D. E. Shaw & Co. | $3.15M | was 0.0% |
| AQR Capital Management | $327,155 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 229 holders, 72.17M shares, $2.73B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 18.50K sh · $684,500
Officer, Director · 18.50K sh · $649,642
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology